Replimune Group (NASDAQ:REPL) Given New $21.00 Price Target at HC Wainwright

Replimune Group (NASDAQ:REPL) had its price target raised by HC Wainwright from $17.00 to $21.00 in a report issued on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other analysts also recently issued research reports about the company. Jefferies Financial Group lifted their price target on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. BMO Capital Markets increased their price objective on Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday, November 22nd. Finally, JPMorgan Chase & Co. boosted their target price on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Replimune Group has an average rating of “Buy” and an average target price of $19.14.

Replimune Group Trading Up 9.9 %

NASDAQ:REPL opened at $13.02 on Wednesday. The business’s 50-day simple moving average is $12.18 and its 200-day simple moving average is $11.28. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The stock has a market capitalization of $890.83 million, a PE ratio of -4.27 and a beta of 1.28.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.07. Sell-side analysts expect that Replimune Group will post -2.91 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. lifted its position in Replimune Group by 17.6% during the second quarter. American Century Companies Inc. now owns 50,785 shares of the company’s stock worth $457,000 after acquiring an additional 7,587 shares during the last quarter. Hsbc Holdings PLC boosted its stake in Replimune Group by 139.1% in the 2nd quarter. Hsbc Holdings PLC now owns 29,344 shares of the company’s stock valued at $253,000 after purchasing an additional 17,072 shares during the period. Point72 DIFC Ltd acquired a new position in Replimune Group in the 2nd quarter valued at $57,000. Cubist Systematic Strategies LLC increased its position in Replimune Group by 282.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock worth $650,000 after buying an additional 53,313 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Replimune Group during the second quarter worth $443,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.